Haemonetics Corporation Common Stock (HAE) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
56/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$76.68
Trend Context
Mixed / range
Latest briefing
What's happening with HAE
prnewswire.com8 Jul 2026
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
gurufocus.com25 Jun 2026
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100
On June 25, 2026, Haemonetics Corp (HAE) shares rose 6.5% today, bringing the current price to $77.62. The stock has experienced a 52-week range between $47.32
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com15 Jun 2026
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026 guidance, suggesting valuation remains attractive.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
12 Jun 2026
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
